优化的增强子RNA在小鼠胚胎干细胞中稳定性的定量评估
November 21st, 2025
该方案通过放线霉素D处理、RT-qPCR和非线性回归分析，定量测量小鼠胚胎干细胞中基因间和基因内增强子RNA的稳定性和半衰期。采用位置特异性归一化策略，以上下文依赖性准确建模eRNA衰变动态。
我们实验室研究表观遗传学，重点关注分子层面的RNA修饰和增强子。我们最近发现，RNA m5C酶Nsun2在小鼠胚胎干细胞中被一种基因内增强子调控。首先，在六孔培养板的孔上预涂2毫升明胶。
在37摄氏度下孵育板10分钟。从每个槽抽取明胶，然后用一毫升PBS清洗一次。将板材置于紫外线下至少15分钟消毒。
每孔用两毫升全细胞培养基将小鼠胚胎干细胞种子撒在明胶涂层板上。在37摄氏度的加湿培养箱中，含5%二氧化碳孵育箱中孵育细胞。接着，将放线霉素D溶解在二甲基亚砜中，制备浓度为每毫升一毫克的存制溶液。
在播种后两天或采集当天，将放线霉素D的原料溶液加入培养基中。在处理后0、5、10、15、20和30分钟采集样本。转录停止后，增强子RNA的表达在5分钟内迅速下降，而信使RNA则较为缓慢，并在30分钟内相对稳定。半衰期分析显示，增强子RNA的半衰期约为两到三分钟，而信使RNA的半衰期显著更长，超过60分钟。
对于Pou5f1基因增强子RNA，归一化为TBP信使RNA或零分钟的周期阈值，也产生了类似的半衰期估计。新生RNA测序数据显示Nsun2增强子区域的RPKM值高于负对照组。RT-qPCR分析确认Nsun2增强子区域中两种基因间增强子RNA的标准化表达高于阴性对照组。
对于基因间增强子所采用的归一化方法是合适的，因为其表达模式相对于阴性对照的模式与使用RPKM观察到的模式一致。我们的研究提供了一种测量和归一化快速降解增强子短半线的方法。我们解决了缺乏明确方法比较基因间和基因内增强子活性的问题。
它简化了数据处理，并允许通过清晰、精确的步骤快速计算mESC衰变。
View the full transcript and gain access to thousands of scientific videos
概述
本协议定量测量了小鼠胚胎干细胞中基因间和基因内增强子RNA的稳定性和半衰期，使用放线菌素D处理、RT-qPCR和非线性回归分析。特定位置的归一化策略被纳入以在依赖于上下文的方式下准确建模eRNA衰减动力学。
关键研究组成部分
科学领域
- 表观遗传学
- RNA修饰
- 增强子生物学
背景
- 增强子RNA（eRNAs）在基因调控中起着关键作用。
- RNA m5C酶Nsun2受基因内增强子调控。
- 小鼠胚胎干细胞作为研究增强子功能的模型。
- 理解eRNA稳定性对于阐明基因表达机制很重要。
研究目的
- 测量小鼠胚胎干细胞中eRNA的稳定性和半衰期。
- 利用放线菌素D处理来评估RNA衰减。
- 应用非线性回归分析来建模eRNA动力学。
使用的方法
- 放线菌素D处理以抑制转录。
- RT-qPCR用于定量eRNA水平。
- 非线性回归分析用于衰减建模。
- 特定位置的归一化策略用于获得准确结果。
主要结果
- 获得了eRNA稳定性的定量测量。
- 确定了基因间和基因内eRNA的半衰期。
- 成功地建模了依赖于上下文的衰减动力学。
- 研究结果有助于理解干细胞中的增强子调控。
结论
- 该协议提供了一种研究eRNA稳定性的可靠方法。
- 结果突出了增强子调控在基因表达中的重要性。
- 未来的研究可以在这些发现的基础上探索eRNA功能。
常见问题
Executive Industry Relevance
Quantitative assessment of enhancer RNA (eRNA) stability in mouse embryonic stem cells addresses a critical gap in understanding transcriptional regulation dynamics during early discovery. Accurate measurement of eRNA decay kinetics enables mechanistic de-risking and informs target validation strategies for gene regulatory elements. This capability supports predictive confidence in modulating enhancer activity for therapeutic discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of enhancer function and regulatory pathway dynamics in pluripotent systems.
- Supports biological de-risking by quantifying rapid turnover of non-coding regulatory RNAs.
- Facilitates functional target validation for enhancer-associated gene expression control.
- Provides quantitative data to inform predictive confidence and portfolio triage decisions.
Screening & Assay Development
- Establishes validated workflows for measuring RNA stability in high-turnover systems.
- Standardizes normalization and decay modeling for reproducible quantitative outputs.
- Prepares robust assay platforms for screening enhancer modulators or RNA stability regulators.
- Enables reliable evaluation of compound effects on enhancer RNA dynamics.
Translational & Preclinical Research
- Aligns with disease-relevant models where enhancer dysregulation impacts gene expression.
- Supports continuity from discovery through preclinical validation of regulatory RNA targets.
- Provides mechanistic insights for risk-adjusted advancement of enhancer-targeted programs.
- Strengthens predictive de-risking for translational biomarker development.
Pipeline & Workflow Integration
This quantitative eRNA stability method integrates into the early discovery-to-lead identification continuum, supporting both hypothesis testing and downstream assay development.
- Discovery Biology: Enables hypothesis-driven testing of enhancer function and RNA turnover in stem cell models.
- Screening: Provides standardized, reproducible decay measurements for assay readiness and compound evaluation.
- Analytics: Delivers quantitative half-life and decay curve outputs for comparative analysis across conditions.
- Translational Research: Connects enhancer RNA dynamics to disease-relevant gene regulation when supported by model context.
- Enterprise Reuse: Offers a reusable framework for regulatory RNA stability assessment across diverse targets and systems.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in enhancer target validation.
- Operational Value: Delivers standardized, scalable, and reproducible RNA stability measurements.
- Strategic Value: Improves go/no-go decisions and capital efficiency by clarifying enhancer function early in the pipeline.
- Portfolio Impact: Enables risk-adjusted prioritization of regulatory RNA targets for advancement.
Implementation Considerations
- Requires expertise in RNA biology, quantitative PCR, and decay modeling analytics.
- Needs access to cell culture, transcriptional inhibition reagents, and RT-qPCR instrumentation.
- Demands cross-team standardization of normalization and data analysis protocols.
- Adaptable to other cell types or enhancer contexts with appropriate validation.
- Short half-life of eRNAs necessitates precise timing and rapid sample processing.
